ACAD Stock Recent News
ACAD LATEST HEADLINES
Airline stocks are down today as investors deal with several bits of bad news for the industry on Tuesday! Starting off the negative news today is Delta Air Lines (NYSE:DAL) with its latest quarterly outlook.
Acadia Pharmaceuticals (NASDAQ: ACAD ) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin. Pimavanserin is a drug in development at Acadia Pharmaceuticals as a treatment for negative symptoms of schizophrenia.
Shares of Acadia Pharmaceuticals Inc. dropped more than 15% in the extended session Monday after one of the pharma company's drugs failed to meet goals of a late-stage trial about a schizophrenia treatment.
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues.
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to loss of $0.26 per share a year ago.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Culper Research said on Thursday it has taken a short position on Acadia Pharmaceuticals' stock.
ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of Prader-Willi Syndrome. PWS is a rare disease characterized by various physical and developmental challenges. Acadia is an established commercial stage company, while Soleno is a clinical stage company focused on PWS.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.